A new study shows that semaglutide reduces heart failure symptoms like fatigue and swelling by bringing down body weight.
The trial was sponsored by Novo Nordisk, which makes Ozempic and Wegovy. Semaglutide was originally developed by the company as a medication to treat type 2 diabetes. GLP-1 hormone
In addition to looking at how the drug may reduce heart failure in people with obesity, Novo Nordisk is researching whether it offers more general cardiovascular benefits. Last month, the company announced that weekly injections of semaglutide over a five-year periodin more than 17,000 people with obesity and a history of cardiovascular disease. The company hasn’t published detailed results from that trial yet, but it is expected to reveal them at a conference later this year.
But Gulati says “that big of a reduction in cardiovascular events tells me there’s something else going on.” She says it’s possible that semaglutide is having an anti-inflammatory effect, for example. “I don’t think we entirely know how the drug works right now,” she says. Based on that 2021 paper, Wong and his colleagues used statistical modeling to estimate how many Americans may benefit from semaglutide. His study,, concluded that if all 93 million US adults who are overweight and obese were prescribed the drug, over it could result in 43 million fewer people with obesity, and over 10 years, prevent up to 1.5 million heart attacks, strokes, and other adverse cardiovascular events.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Weight-Loss Drugs Ozempic and Wegovy Can Also Protect the HeartA new study shows that semaglutide reduces heart failure symptoms like fatigue and swelling by bringing down body weight.
Read more »
Novo Nordisk launches weight-loss drug Wegovy in UKNovo Nordisk launched its weight-loss injection Wegovy in Britain on Monday, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to keep up with soaring demand.
Read more »
Weight-Loss Drug Wegovy Launches In U.K. As Shares Of Drugmaker Novo Nordisk Hit New PeakIn August, Novo Nordisk's CEO said it could “take quite some years” for the company to meet soaring demand for the popular drug.
Read more »
Novo Nordisk's Wegovy weight loss drug launches in the UKNovo Nordisk launched its Wegovy weight loss injection in the U.K. Monday, furthering the drug’s rollout in Europe despite ongoing supply constraints.
Read more »
Wegovy makes UK weight-loss debut even as Novo struggles with supplies By ReutersWegovy makes UK weight-loss debut even as Novo struggles with supplies
Read more »
Why is Wegovy weight-loss jab so hard to get access to?Soaring US demand and high drug prices may be keeping the weight loss injections from other nations
Read more »